Description

Froxiprost is a synthetic prostaglandin analog, a high-purity active pharmaceutical ingredient (API) with significant biological activity. Its primary value lies in its potent and selective pharmacological effects, making it a critical intermediate for advanced pharmaceutical research and development. This compound is essential for researchers and manufacturers in the pharmaceutical industry, particularly those developing targeted therapeutics in areas such as ophthalmology and reproductive health. Froxiprost CAS NO 62559-74-4 is supplied under stringent quality control to ensure reliability for sensitive applications.

Application

Froxiprost serves as a key building block in several advanced pharmaceutical and research contexts.

• Pharmaceutical Intermediate: Primary use as a critical raw material in the synthesis of proprietary prostaglandin-based drugs.
• Ophthalmic Research: Investigation and development of novel treatments for glaucoma and ocular hypertension due to its intraocular pressure-lowering potential.
• Reproductive Health R&D: Study of its effects on smooth muscle and vascular tissues for potential applications in fertility and obstetrics.
• Biochemical Standard: Utilized as a reference standard in analytical laboratories for method development and quality control of related compounds.
• Preclinical Studies: Employed in animal model research to elucidate the pharmacokinetics and pharmacodynamics of prostaglandin analogs.
• Contract Manufacturing: Supplied to CDMOs (Contract Development and Manufacturing Organizations) for the production of clinical trial materials.

Basic Information

Product Name	Froxiprost
CAS No.	62559-74-4
Molecular Formula	C₂₃H₂₉FO₅
Molecular Weight	404.47 g/mol
Synonyms	9,11,15-Trihydroxy-16-(3-trifluoromethylphenoxy)-17,18,19,20-tetranorprosta-5,13-dien-1-oic acid; 16-(3-Trifluoromethylphenoxy)tetranor PGF2α; Prostaglandin F2α analog; Fluprostenol isomer; 16-(m-Trifluoromethylphenoxy)tetranor PGF2α; 9α,11α,15α-Trihydroxy-16-(3-trifluoromethylphenoxy)-17,18,19,20-tetranor-5-cis,13-trans-prostadienoic acid
EINECS	Contact for details

Quality Control

Our Froxiprost is manufactured under a strict quality management system. Each batch undergoes comprehensive analytical testing, including HPLC for purity, residual solvent analysis, and identity confirmation by IR and MS, to ensure it meets the high standards required for pharmaceutical research. We provide full traceability and Certificates of Analysis (COA) are available for every shipment, detailing all critical quality attributes.

Storage

Preserve in a tightly closed container, protected from light. Store under an inert atmosphere (e.g., nitrogen or argon) at a controlled room temperature of 15-25°C (59-77°F) to prevent oxidation and degradation. The container should be kept in a cool, dry, and well-ventilated area, separate from incompatible materials.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.5%
Related Substances (HPLC)	Total impurities ≤ 1.5% Any single unknown impurity ≤ 0.5%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Loss on Drying	≤ 0.5%
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.